NewAmsterdam Pharma Co N.V. (NAMS) stock — the fundamentals (P/E, market cap, valuation) and every material event, decoded in plain English.
Key numbers for NewAmsterdam Pharma Co N.V. (NAMS): P/E ratio, market cap, profit margins, returns, and whether the stock looks cheap or expensive versus its own 5-year range.
AllSight quality score: 35/100 — a percentile rank of NewAmsterdam Pharma Co N.V.’s fundamentals against Manufacturing peers, weakest on growth. A quality ranking, not a price prediction.
| Market cap | $2.9B |
| P / S | 405.6× |
| EV / EBITDA | -10.1× |
| Gross margin | 100.0% |
| Operating margin | -3432.2% |
| Net margin | -3644.2% |
| Return on equity | -41.1% |
| ROIC | -117.9% |
| Revenue growth | -88.9% |
| Debt / equity | 0.0× |
| Dividend yield | 0.0% |
Is NewAmsterdam Pharma Co N.V. overvalued? P/S looks fair vs its 5-year range; P/B looks fair vs its 5-year range.
Independent of the events above — derived from NewAmsterdam Pharma Co N.V.’s own financial statements and shown as context, never as advice.
About AllSight · Editorial standards & method · Contact